Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 21;13:6246. doi: 10.1038/s41467-022-34042-w

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — a Volcano plot of differentially expressed core splicing factors (n = 134) between the TCGA-OV cohort (n = 374) and normal tissue in GTEx datasets (n = 180). |log2FC| > 1 and an adjusted p value < 0.05 were considered significant. b, c Forrest plot of the hazard ratio for the association between 13 dysregulated splicing factors and overall survival (n = 1023) and progression-free survival (n = 1001) in patients with SOC from the Kaplan–Meier Plotter database. The cohort of patients with SOC was split by auto-select cutoff. Prognostic splicing factors (red) with a p < 0.05 were considered statistically significant. d, e MTT assay and flow cytometry determined the HEYA8 cell viability and apoptosis cell percentage after siBUD31, siSF3B1, siSF3B4, siSRSF4, siMATR3, and siCHERP treatment for 72 h (n = 3 biologically independent experiments). *p < 0.05, **p < 0.01. f BUD31 mRNA expression was analyzed in the TCGA-OV cohort (n = 374) and normal tissue in GTEx datasets (n = 180). g BUD31 protein level was analyzed in SOCs (n = 93) and FTs (n = 25) from the CPTAC dataset. SOC samples were classified into Stage 1 (n = 2), Stage 3 (n = 75), and Stage 4 (n = 16) according to individual cancer stage. The bounds of the box were the upper and lower quartile with the median value in the center. The whiskers indicated the minima and maxima. h Statistical analysis of BUD31 expression from IHC staining of the tissue microarray containing 149 samples of SOCs and 73 samples of FTs. i Representative images of IHC staining with high, medium, and low BUD31 expression in our tissue microarray. j, k Kaplan–Meier analysis of the correlation between BUD31 expression and overall survival and progression-free survival of ovarian cancer patients based on data from our tissue microarray. The 95% confidence interval was shown as dotted lines. l, m Kaplan–Meier analysis of the correlation between BUD31 expression and overall survival and progression-free survival of ovarian cancer patients based on the Kaplan–Meier Plotter cohort. The p value was obtained by log-rank test (b, c, j, k, l, m), two-tailed unpaired Student’s t-test (d, e, f, g), and Chi-square test (h). Data are presented as means ± SD unless otherwise stated.